Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Report Date: May 7, 2024 (Event Date)
Reporting Period: First Quarter ended March 31, 2024
Context: This filing announces the scheduling of a conference call and the subsequent release of financial results for the first quarter of 2024. The company is classified as an emerging growth company.
Key Financial Metrics
The provided Form 8-K text serves as a notification of the financial results release and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.2) dated May 9, 2024, which is not included in the source text.
Material Changes
No material changes to financial performance or operations are quantified in this filing. The document solely references the issuance of a press release containing the Q1 2024 results and a corporate update.
Guidance, Outlook, and Management Commentary
- Conference Call: The Company held a conference call on May 9, 2024, at 4:30 PM Eastern Time to discuss Q1 results and provide a corporate update.
- Exhibits: The filing includes a press release dated May 7, 2024 (Exhibit 99.1) and a press release dated May 9, 2024 (Exhibit 99.2) containing the financial results and business update.
- Legal Disclaimer: The information in this report and its exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific Q1 2024 financial figures (revenue, net loss, cash position) in the May 9, 2024 press release (Exhibit 99.2).
- Review the "corporate update" details provided during the May 9, 2024 conference call for operational milestones or pipeline updates.
- Confirm the company's cash runway and burn rate based on the Q1 results to assess liquidity needs.
- Check for any forward-looking guidance or revised timelines for clinical trials mentioned in the May 9 press release.